What's Happening?
Arrowhead Pharmaceuticals has announced the completion of enrollment for its global Phase 3 YOSEMITE clinical trial of zodasiran, an investigational RNA interference therapeutic. This drug is being developed to treat homozygous familial hypercholesterolemia
(HoFH), a rare genetic condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and early onset cardiovascular disease. The trial, initially designed for 60 participants, has enrolled 70 due to strong interest from patients and physicians. The study aims to evaluate the efficacy and safety of zodasiran in reducing LDL-C levels in patients with HoFH, who are on maximally tolerated lipid-lowering therapy. The trial is expected to conclude in mid-2027, after which Arrowhead plans to seek regulatory approval in various regions.
Why It's Important?
The completion of enrollment in the YOSEMITE study marks a significant milestone in addressing the unmet medical needs of patients with HoFH, a condition with limited treatment options. HoFH patients face a high risk of developing atherosclerotic cardiovascular disease due to elevated LDL-C levels. Zodasiran offers a novel approach by targeting ANGPTL3, a protein involved in lipid metabolism, potentially providing a new treatment avenue distinct from conventional therapies. Successful outcomes from this trial could lead to a new therapeutic option for managing this challenging condition, impacting the lives of patients who currently have few effective treatments available.
What's Next?
Following the completion of the YOSEMITE study in mid-2027, Arrowhead Pharmaceuticals plans to pursue regulatory approvals for zodasiran across multiple geographies. If the trial results are favorable, this could lead to the introduction of a new treatment for HoFH, potentially improving patient outcomes and expanding the therapeutic landscape for this rare disorder. The company will likely engage with regulatory bodies to discuss the trial results and the potential for zodasiran to meet the needs of patients with this high-risk condition.
